Compound News and Research

RSS

Spinifex secures major investment to develop pain drug

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured venture capital investment of A$12 million from GBS Venture Partners Limited, Brandon Capital Partners and Uniseed to fund the development of its pain management drug, EMA401.

2 Sep 2008

New stem cell tools to aid drug development

Scientists have designed, developed and tested new molecular tools for stem cell research to direct the formation of certain tissue types for use in drug development programmes.

2 Sep 2008

Fibrin-derived peptide FX06 reduces cardiac reperfusion injury

Data presented today at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack.

2 Sep 2008

Anti-itching drug clemizole shows promise against hepatitis C

The fight against the liver disease hepatitis C has been at something of an impasse for years, with more than 150 million people currently infected, and traditional antiviral treatments causing nasty side effects and often falling short of a cure. Using a novel technique, medical and engineering researchers at Stanford University have discovered a vulnerable step in the virus' reproduction process that in lab testing could be effectively targeted with an obsolete antihistamine.

31 Aug 2008

Thiazolidinediones - diabetes drugs carry significant cardiovascular risks

A class of oral drugs used to treat type 2 diabetes may significantly increase the risk of serious cardiovascular events, according to an editorial published online in Heart Wednesday by two Wake Forest University School of Medicine faculty members.

28 Aug 2008

Galapagos acquires structure-based drug discovery from Sareum

Galapagos NV and Sareum Holdings plc has announced today that Galapagos has acquired Sareum's assets in drug discovery services, for a total cash consideration of EUR 695,000 (£553,000). These assets will position Galapagos' service division BioFocus DPI strongly in the growing field of structure-based drug discovery.

26 Aug 2008

Could a substance from the jasmine flower hold the key to an effective new therapy to treat cancer?

Prof. Eliezer Flescher of The Sackler Faculty of Medicine, Tel Aviv University thinks so. He and his colleagues have developed an anti-cancer drug based on a decade of research into the commercial applications of the compound Jasmonate, a synthetic compound derived from the flower itself.

25 Aug 2008

NicOx updates on PF-03187207 and research collaboration with Pfizer

NicOx S.A. has announced the results of a dose-ranging phase 2 study conducted with PF‑03187207 in Japanese patients with glaucoma by its partner Pfizer Inc. PF-03187207 is a nitric oxide-donating prostaglandin analog. The study was designed to compare the safety and efficacy of several doses of PF-03187207 to Xalatan (latanoprost) and enrolled 112 Japanese patients with primary open-angle glaucoma or ocular hypertension.

25 Aug 2008

Intel's CTO says technology will bring man and machine much closer together by 2050

Intel Corporation's chief technology officer took a fascinating look at how technology will bring man and machine much closer together by 2050.

21 Aug 2008

Scientists uncover molecule that keeps pathogens like salmonella in check

Scientists at UT Southwestern Medical Center have found a potential new way to stop the bacteria that cause gastroenteritis, tularemia and severe diarrhea from making people sick.

21 Aug 2008

Codeine use may be risky for some breastfeeding mothers

Using pain treatments which contain codeine may be risky for some breastfeeding mothers, according to researchers at The University of Western Ontario, and the Hospital for Sick Children (SickKids) in Toronto.

20 Aug 2008

One night without sleep increases chemical dopamine in the human brain

Because drugs that increase dopamine, like amphetamines, promote wakefulness, the findings offer a potential mechanism explaining how the brain helps people stay awake despite the urge to sleep. However, the study also shows that the increase in dopamine cannot compensate for the cognitive deficits caused by sleep deprivation.

19 Aug 2008

Stanford develop method to overcome multiple drug resistant diseases

Many drugs once considered Charles Atlases of the pharmaceutical realm have been reduced to the therapeutic equivalent of 97-pound weaklings as the diseases they once dispatched with ease have developed resistance to them.

18 Aug 2008

Mosquitoes smell DEET and stay away

Spray yourself with a DEET-based insect repellent and the mosquitoes will leave you alone. But why? They flee because of their intense dislike for the smell of the chemical repellent and not because DEET jams their sense of smell, report researchers at the University of California, Davis.

18 Aug 2008

Spice-based compound to fight against cancer

Seeking to improve on nature, scientists used a spice-based compound as a starting point and developed synthetic molecules that, in lab settings, are able to kill cancer cells and stop the cells from spreading.

17 Aug 2008

Diakron licenses anticoagulant drug candidate from Merck

Diakron Pharmaceuticals, Inc. announced today the signing of an exclusive license agreement for a novel investigational oral anticoagulant drug candidate discovered and developed through Phase I clinical trials by Merck & Co. Inc. Under the terms of the agreement, Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide.

13 Aug 2008

NanoBio vaccine for hepatitis B shows promise

Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas. The disease and its complications cause an estimated 1 million deaths globally each year.

13 Aug 2008

Oxygen Biotherapeutics develops gel version of Oxycyte for treating surface wounds

Oxygen Biotherapeutics, Inc. has announced that the company has developed a gel-like form of Oxycyte that it intends to investigate as a topical application for open wounds, abrasions and burns. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

12 Aug 2008

PET scans spot signs of early Alzheimer's

Scientists in Finland say a type of imaging technique known as positron emission tomography (PET) scanning may be a useful and non-invasive way of diagnosing the early stages of Alzheimer’s disease.

11 Aug 2008